Genmab’s collaboration partner, J&J, has released better than expected sales numbers for Darzalex for Q2, but the beat was largely due to one-off adjustments. On a separate note, Genmab plans to raise c.$500m, through the listing of ADSs in the US, to fund its R&D investments and be commercially launch-ready.
17 Jul 2019
Q2 sales above expectations; US listing on the cards
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q2 sales above expectations; US listing on the cards
Genmab A/S (GMAB:WBO) | 0 0 1.3% | Mkt Cap: 66,508m
- Published:
17 Jul 2019 -
Author:
Sumit Sayal -
Pages:
2
Genmab’s collaboration partner, J&J, has released better than expected sales numbers for Darzalex for Q2, but the beat was largely due to one-off adjustments. On a separate note, Genmab plans to raise c.$500m, through the listing of ADSs in the US, to fund its R&D investments and be commercially launch-ready.